XML 64 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue - Incyte Corporation (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended
Mar. 31, 2023
USD ($)
Oct. 31, 2017
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2018
USD ($)
performanceObligation
Collaboration and Other Agreements [Line Items]              
Revenues       $ 58,749 $ 151,941 $ 77,447  
Incyte MGA012 Agreement | Incyte Corporation (Incyte)              
Collaboration and Other Agreements [Line Items]              
Non-refundable upfront payment     $ 150,000        
Amounts recognized $ 15,000     115,000      
Number of performance obligations | performanceObligation             2
Transaction price   $ 154,000          
Clinical trial activities selling price amount             $ 4,000
Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)              
Collaboration and Other Agreements [Line Items]              
Potential proceeds from royalties percent   15.00%          
Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)              
Collaboration and Other Agreements [Line Items]              
Potential development and regulatory milestone payments   $ 435,000          
Potential commercial milestone payments   $ 330,000          
Potential proceeds from royalties percent   24.00%          
Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)              
Collaboration and Other Agreements [Line Items]              
Revenues   $ 150,000   15,000 30,000 15,000  
Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)              
Collaboration and Other Agreements [Line Items]              
Revenues       1,900 700 1,500  
Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)              
Collaboration and Other Agreements [Line Items]              
Revenues       $ 4,200 $ 300 $ 7,800